Identification of Polyphenol Derivatives as Novel SARS-CoV-2 and DENV Non-Nucleoside RdRp Inhibitors

Molecules. 2022 Dec 25;28(1):160. doi: 10.3390/molecules28010160.

Abstract

The Coronavirus Disease 2019 (COVID-19) and dengue fever (DF) pandemics both remain to be significant public health concerns in the foreseeable future. Anti-SARS-CoV-2 drugs and vaccines are both indispensable to eliminate the epidemic situation. Here, two piperazine-based polyphenol derivatives DF-47 and DF-51 were identified as potential inhibitors directly blocking the active site of SARS-CoV-2 and DENV RdRp. Data through RdRp inhibition screening of an in-house library and in vitro antiviral study selected DF-47 and DF-51 as effective inhibitors of SARS-CoV-2/DENV polymerase. Moreover, in silico simulation revealed stable binding modes between the DF-47/DF-51 and SARS-CoV-2/DENV RdRp, respectively, including chelating with Mg2+ near polymerase active site. This work discovered the inhibitory effect of two polyphenols on distinct viral RdRp, which are expected to be developed into broad-spectrum, non-nucleoside RdRp inhibitors with new scaffold.

Keywords: DENV; RdRp; SARS-CoV-2; non-nucleoside; polyphenol.

MeSH terms

  • Antiviral Agents / chemistry
  • COVID-19*
  • Humans
  • Molecular Docking Simulation
  • Polyphenols / pharmacology
  • RNA-Dependent RNA Polymerase / metabolism
  • SARS-CoV-2* / metabolism

Substances

  • Polyphenols
  • RNA-Dependent RNA Polymerase
  • Antiviral Agents